International Journal of Brain Research

Objective To analyse the effect of using temozolomide combined with whole brain radiotherapy in the treatment of non-small cell lung cancer metastases. Methods Non-small cell lung cancer metastatic tumour patients admitted to our hospital from September 2022 to September 2023 were selected and divided into two groups on average, a total of 90 cases i.e., divided into the study group of temozolomide combined with whole-brain radiotherapy (n=45) and the reference group of whole-brain radiotherapy (n=45), and the statistical results were compared. Results The disease remission rate and control rate of the patients in the study group were higher than those in the reference group, and both the tumour marker content and immune function were better than those in the reference group after treatment (P < 0.05). Conclusion The use of temozolomide combined with whole-brain radiotherapy in the treatment of non-small cell lung cancer brain metastases has a certain effect, which can not only reduce the impairment of immune function of the patients, but also reduce the content of tumour markers.

Non-small cell lung cancer metastases; Whole brain radiotherapy; Temozolomide; Effect